These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 4905918)

  • 41. [Results of studying a live mumps vaccine from strain L-3 manufactured by the Moscow Research Institute of Viral Preparations. The epidemiological effectiveness of the vaccine].
    Unanov SS; Bochkov RA; Alekseeva AK; Kaptosova TI; Levchenko EN
    Vopr Virusol; 1977; (1):59-61. PubMed ID: 143795
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks?
    Dayan GH; Rubin S
    Clin Infect Dis; 2008 Dec; 47(11):1458-67. PubMed ID: 18959494
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mumps outbreaks in Canada and the United States: time for new thinking on mumps vaccines.
    Peltola H; Kulkarni PS; Kapre SV; Paunio M; Jadhav SS; Dhere RM
    Clin Infect Dis; 2007 Aug; 45(4):459-66. PubMed ID: 17638194
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Experience with live-virus mumps vaccine.
    J Iowa Med Soc; 1968 Sep; 58(9):955-7. PubMed ID: 5683277
    [No Abstract]   [Full Text] [Related]  

  • 45. Studies on live mumps virus vaccine. 3. Evaluation of newly developed live mumps virus vaccine.
    Yamanishi K; Takahashi M; Kurimura T; Ueda S; Minekawa Y
    Biken J; 1970 Sep; 13(3):157-61. PubMed ID: 4992054
    [No Abstract]   [Full Text] [Related]  

  • 46. Studies on live attenuated mumps vaccine. I. Comparative field trials with two different live vaccines.
    Isomura S; Asano Y; Hon AS; Miyata T; Suzuki S
    Biken J; 1973 Jun; 16(2):39-42. PubMed ID: 4729799
    [No Abstract]   [Full Text] [Related]  

  • 47. Measles and mumps immunization: benefit versus risk factors.
    Krugman S
    Dev Biol Stand; 1979; 43():253-7. PubMed ID: 520672
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mumps vaccination.
    Hilleman MR
    Mod Trends Med Virol; 1970; 2(0):241-61. PubMed ID: 5527958
    [No Abstract]   [Full Text] [Related]  

  • 49. Combined live measles-mumps virus vaccine.
    Weibel RE; Villarejos VM; Hernández G; Stokes J; Buynak EB; Hilleman MR
    Arch Dis Child; 1973 Jul; 48(7):532-6. PubMed ID: 4719108
    [No Abstract]   [Full Text] [Related]  

  • 50. Long-term follow-up for immunity after monovalent or combined live measles, mumps, and rubella virus vaccines.
    Weibel RE; Buynak EB; McLean AA; Hilleman MR
    Pediatrics; 1975 Sep; 56(3):380-7. PubMed ID: 1161394
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Experience with live rubella virus vaccine combined with live vaccines against measles and mumps.
    Smorodintsev AA; Nasibov MN; Jakovleva NV
    Bull World Health Organ; 1970; 42(2):283-9. PubMed ID: 5310140
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Persistence of antibody after administration of monovalent and combined live attenuated measles, mumps, and rubella virus vaccines.
    Weibel RE; Buynak EB; McLean AA; Hilleman MR
    Pediatrics; 1978 Jan; 61(1):5-11. PubMed ID: 263873
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Estimation of the efficacy of three strains of mumps vaccines during an epidemic of mumps in the Geneva canton (Switzerland)].
    Chamot E; Toscani L; Egger P; Germann D; Bourquin C
    Rev Epidemiol Sante Publique; 1998 Mar; 46(2):100-7. PubMed ID: 9592852
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical studies with virulent and attenuated mumps viruses.
    Ennis FA; Douglas RD; Hopps HE; Meyer HM; Brown ER; Hobbins TE; Biehusen FC
    Am J Epidemiol; 1969 Feb; 89(2):176-83. PubMed ID: 5765957
    [No Abstract]   [Full Text] [Related]  

  • 55. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
    Gerike E; Tischer A
    Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mumps virus vaccine.
    Smith MH
    Pediatrics; 1969 May; 43(5):907-9. PubMed ID: 5786553
    [No Abstract]   [Full Text] [Related]  

  • 57. [Antibody formation following immunization with mono- and bivalent mumps-(measles-)vaccine (author's transl)].
    Sarateanu DE; Allerdist H; Ehrengut W
    Immun Infekt; 1978 Feb; 6(1):33-7. PubMed ID: 627405
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Live, attenuated mumps-virus vaccine. 3. Clinical and serologic aspects in a field evaluation.
    Weibel RE; Stokes J; Buynak EB; Whitman JE; Hilleman MR
    N Engl J Med; 1967 Feb; 276(5):245-51. PubMed ID: 6016060
    [No Abstract]   [Full Text] [Related]  

  • 59. Evaluation of a new mumps vaccine. Mumps virus vaccine, live, attenuated (Mumpsvax).
    JAMA; 1969 Sep; 209(13):2042. PubMed ID: 5820267
    [No Abstract]   [Full Text] [Related]  

  • 60. [Vaccination against epidemic parotitis].
    Midulla M; Chiavelli S
    Pediatr Med Chir; 1984; 6(1):25-30. PubMed ID: 6442412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.